Addressing disorders related to the central nervous system (CNS) remains a complex
challenge because of the presence of the blood-brain barrier (BBB), which restricts the entry …

Alzheimer's disease (AD), as a neurodegenerative disorder, usually develops slowly but
gradually worsens. It accounts for approximately 70% of dementia cases worldwide, and is …

The present study investigates the brain-targeted efficiency of atomoxetine (AXT)-loaded
nanostructured lipid carrier (NLC)-laden thermosensitive in situ gel after intranasal …

Intranasal (IN) drug delivery is a non-invasive and effective route for the administration of
drugs to the brain at pharmacologically relevant concentrations, bypassing the blood–brain …

Alzheimer's disease (AD) is the most common form of dementia, with a high impact
worldwide, accounting for more than 46 million cases. The continuous increase of AD …

The exponential growth of nanotechnology has focused on therapeutic pursuits, notably for
brain disorders. Nanocarriers have submicron particle sizes, typically around 500 nm. Over …

Purpose Amorphous solid dispersions (ASD) for nasal delivery offer the opportunity to
increase drug release performance, while using polymers with mucoadhesive properties …

The nasal route has been investigated as a promising alternative for drug delivery to the
central nervous system, avoiding passage through the blood–brain barrier and improving …

Second-generation antipsychotics, quetiapine hemifumarate (QF), exhibited highly active
against negative and positive signs of psychosis. However, contemporary reports have …

Cisplatin (cis) is a first-line chemotherapeutic used for the treatment of intractable pediatric
brainstem glioma (PBSG). Its therapeutic effect in PBSG is, however, critically challenged by …